-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Lundbeck announced that it has reached a final agreement with AprilBio of South Korea
According to the terms of the license agreement, Lundbeck will pay AprilBio a one-time payment of US$16 million in cash
The press release shows that too many people around the world suffer from brain diseases-complex diseases are often invisible to others, but they have brought huge losses to individuals, families and society
APB-A1 is a neutralizing anti-CD40L antibody-like drug candidate with an innovative molecular design that blocks the CD40L/CD40 costimulatory interaction
APB-A1 is a human high-affinity anti-CD40L antibody-like fusion protein designed to inhibit the CD40L/CD40 pathway by neutralizing and activating CD40L on T cells, thereby significantly weakening the initiated immune response
(The original text has been deleted)
Reference materials:
[1] Lundbeck receives exclusive rights to APB-A1, an innovative phase I-ready bio-therapeutic for the treatment of neuroimmune diseases from AprilBio.